We talked with surgeon Dr. Jeff Singer, a senior fellow at the Cato Institute, who says that industry claims about the risks of expanding access to methadone for opioid use disorder don’t add up. Here, Dr. Singer makes the case that methadone diversion is largely a symptom of poor access to this lifesaving medication.